IBSA Institut Biochimique SA v. Accord Healthcare Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: IBSA Institut Biochimique SA (Swiss Confederation), IBSA Pharma Inc. (Delaware), and Altergon SA (Swiss Confederation)
  • Defendant: Accord Healthcare, Inc. (North Carolina)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:23-cv-00054, D.N.J., 04/19/24
• Venue Allegations: Plaintiffs allege venue is proper in the District of New Jersey because Defendant conducts substantial business in the state, has purposefully availed itself of the state's laws, and has previously consented to jurisdiction and venue in the district in prior patent litigation.
• Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' Tirosint®-SOL product constitutes an act of infringement of three patents related to stable oral solutions of levothyroxine.
• Technical Context: The technology concerns pharmaceutical formulations for levothyroxine (T4 thyroid hormone), a widely used treatment for hypothyroidism, focusing on creating a stable, alcohol-free liquid solution that minimizes degradation and allows for more reliable patient dosing.
• Key Procedural History: This action was triggered by Defendant's submission of ANDA No. 218008 and subsequent notice letters containing Paragraph IV certifications. The first letter, dated November 22, 2022, challenged two of the asserted patents, and a second letter, dated February 20, 2024, challenged the third, alleging that the patents are invalid, unenforceable, or will not be infringed by the proposed generic product. All three patents-in-suit are listed in the FDA's "Orange Book" for Tirosint®-SOL.

Case Timeline

Date	Event
2016-10-18	Earliest Priority Date for '538 and '913 Patents
2019-03-01	Earliest Priority Date for '382 Patent
2020-01-21	U.S. Patent No. 10,537,538 Issues
2021-08-24	U.S. Patent No. 11,096,913 Issues
2022-02-08	U.S. Patent No. 11,241,382 Issues
2022-11-22	Defendant Sends First Notice Letter ('538 and '913 Patents)
2024-02-20	Defendant Sends Second Notice Letter ('382 Patent)
2024-04-19	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,537,538 - High-Stability Packaged Solutions of T4 Thyroid Hormone

The Invention Explained

• Problem Addressed: The patent's background section describes the challenge that liquid solutions of the thyroid hormone T4 are often unstable and can prematurely convert to T3, a significantly more potent hormone '538 Patent, col. 2:16-23 This unpredictable conversion can lead to inaccurate dosing and potential patient harm from over- or under-dosing '538 Patent, col. 2:23-29
• The Patented Solution: The invention claims to solve this problem with an alcohol-free, water-glycerol solution of T4 hormone that is packaged in a specific multi-barrier system '538 Patent, abstract This system involves a primary plastic container (e.g., made of low-density polyethylene) which is itself placed inside a sealed, laminated sachet, creating multiple layers of protection from the external environment to enhance stability '538 Patent, col. 2:55-67
• Technical Importance: The invention provides a liquid T4 formulation with improved stability, aiming to deliver a more reliable and constant amount of the hormone, which is critical for patients requiring chronic thyroid replacement therapy '538 Patent, col. 6:45-53

Key Claims at a Glance

• Independent Claim 1 is asserted Compl. ¶24
• Essential elements of Claim 1:
  • A ready-to-use pharmaceutical preparation of T4 thyroid hormone packaged in a single dose container.
  • The container is pre-filled with a liquid pharmaceutical composition "consisting essentially of" T4 hormone dissolved in an alcohol-free solution of 85% glycerol in water, and optionally T3 hormone below 2.5%.
  • The single dose container is a "one-component LDPE plastic container."
  • The plastic container is "placed in a sealed sachet" made of specific laminated films.
• The complaint alleges infringement of claims 1-8, thereby reserving the right to assert dependent claims Compl. ¶24

U.S. Patent No. 11,096,913 - High-Stability Packaged Solutions of T4 Thyroid Hormone

The Invention Explained

• Problem Addressed: As a continuation of the application leading to the '538 Patent, this patent addresses the same technical problem: the premature conversion of T4 to T3 in liquid formulations during storage, which complicates the establishment of a suitable and safe dosage regimen '913 Patent, col. 2:15-18
• The Patented Solution: The invention is a pharmaceutical preparation comprising a container pre-filled with a liquid composition "consisting essentially of" T4 hormone dissolved in an "alcohol-free and preservative-free solution of 85% glycerol in water" '913 Patent, claim 1 Unlike the '538 Patent, which claims the specific combination of an inner container and an outer sachet, this patent focuses on the inherent stability of the specific preservative-free formulation when stored in a single-dose plastic container '913 Patent, abstract '913 Patent, col. 11:60-67
• Technical Importance: This formulation offers a stable liquid dosage form that avoids alcohol and preservatives, which may be advantageous for patients on chronic therapy who wish to avoid these additional excipients '913 Patent, col. 6:62-67

Key Claims at a Glance

• Independent Claim 1 is asserted Compl. ¶31
• Essential elements of Claim 1:
  • A pharmaceutical preparation of T4 thyroid hormone.
  • The preparation comprises a container pre-filled with a liquid composition "consisting essentially of" T4 hormone dissolved in an "alcohol-free and preservative-free solution of 85% glycerol in water," and optionally T3 hormone below 2.5%.
  • The container is a "single dose plastic container."
• The complaint alleges infringement of claims 1-9, reserving the right to assert dependent claims Compl. ¶31

U.S. Patent No. 11,241,382 - Administration Regimen of Compositions of T4 Thyroid Hormone with High Oral Absorption

• Technology Synopsis: The patent addresses the problem that T4 hormone absorption is significantly reduced when administered close to a meal, particularly breakfast foods like coffee, requiring patients to wait long periods between dosing and eating '382 Patent, col. 2:12-27 The patented solution is a method of treatment using a specific alcohol-free, water-glycerol T4 solution which, the patent asserts, can be administered within a much shorter time interval (less than 30 minutes) before a meal without clinically significant malabsorption, thereby improving patient compliance '382 Patent, abstract '382 Patent, col. 2:50-58
• Asserted Claims: Claims 1-20 are asserted Compl. ¶38 Independent claims are 1 and 11.
• Accused Features: The complaint alleges that Defendant's sale, offer for sale, and commercial manufacture of its generic product would induce infringement of the claimed methods of treatment Compl. ¶39 The infringement theory is based on the premise that the labeling for Defendant's product will instruct or encourage patients and physicians to use it according to the patented administration regimen Compl. ¶39

III. The Accused Instrumentality

Product Identification

• Defendant's generic levothyroxine sodium oral solution, for which Abbreviated New Drug Application (ANDA) No. 218008 was submitted to the FDA ("Accord's Product") Compl. ¶1 Compl. ¶11 Compl. ¶18

Functionality and Market Context

• Accord's Product is a proposed generic version of Plaintiffs' Tirosint®-SOL, an oral solution for treating hypothyroidism Compl. ¶1
• The ANDA seeks approval for the same dosage strengths as Tirosint®-SOL, which range from 13 mcg/mL to 200 mcg/mL Compl. ¶16 Compl. ¶18
• The complaint alleges that Accord's ANDA relies on the Tirosint®-SOL New Drug Application and contains data purporting to demonstrate the bioequivalence of Accord's Product Compl. ¶19 The complaint does not provide specific details about the composition or packaging of Accord's Product, as is typical in ANDA litigation prior to discovery.

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed mapping of the accused product's features to the claim elements, instead alleging that the commercial manufacture, use, or sale of Accord's Product would infringe the asserted claims Compl. ¶24 Compl. ¶31 The infringement allegations are premised on the statutory framework for ANDA litigation, where the filing of an ANDA for a product asserted to be bioequivalent to a branded drug is the act of infringement. The following chart summarizes the allegations based on this premise.

10,537,538 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A ready-to-use pharmaceutical preparation of T4 thyroid hormone packaged in a single dose container which is pre-filled with a liquid pharmaceutical composition consisting essentially of: T4 thyroid hormone dissolved in an alcohol-free solution of 85% glycerol in water...	Accord's Product, as a proposed generic of Tirosint®-SOL, is alleged to be a liquid T4 composition in an alcohol-free, 85% glycerol-in-water solution.	¶18; ¶19	col. 11:50-51
wherein the single dose container is a one-component LDPE plastic container,	Accord's Product is alleged to be packaged in a one-component low-density polyethylene (LDPE) plastic container.	¶18; ¶19	col. 2:65-66
placed in a sealed sachet consisting of laminated films made of a plurality of different materials selected from the following: polyethylene, aluminum, polyethylene terephthalate...	The LDPE container for Accord's Product is alleged to be secondarily packaged in a sealed, laminated sachet as specified.	¶18; ¶19	col. 2:66-67

11,096,913 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A pharmaceutical preparation of T4 thyroid hormone comprising a container pre-filled with a liquid pharmaceutical composition consisting essentially of: T4 thyroid hormone dissolved in an alcohol-free and preservative-free solution of 85% glycerol in water...	Accord's Product, as a proposed generic of Tirosint®-SOL, is alleged to be a liquid T4 composition in an alcohol-free, preservative-free, 85% glycerol-in-water solution.	¶18; ¶19	col. 12:1-2
wherein the container is a single dose plastic container.	Accord's Product is alleged to be packaged in a single-dose plastic container.	¶18; ¶19	col. 8:5-7

Identified Points of Contention

• Factual Questions: A primary point of contention will be factual: does the formulation and packaging of the product described in Accord's ANDA actually meet every limitation of the asserted claims? The complaint does not provide these details, which will be a central focus of discovery.
• Scope Questions ('538 and '913 Patents): The interpretation of the phrase "consisting essentially of" will be critical. The dispute may center on whether Accord's formulation contains any unlisted excipients and, if so, whether those excipients materially affect the "basic and novel properties" of the invention-namely, the enhanced stability of T4 and the reduced conversion to T3 '538 Patent, col. 2:49-52
• Scope Questions ('538 Patent): A potential dispute may arise over whether Accord's packaging, if different from the specific embodiments, still falls within the scope of a "one-component LDPE plastic container" placed within a "sealed sachet" made of the claimed materials.

V. Key Claim Terms for Construction

• The Term: "consisting essentially of" '538 Patent, claim 1 '913 Patent, claim 1
• Context and Importance: This transitional phrase is narrower than "comprising" and broader than "consisting of." It limits the claimed composition to the specified ingredients and those that do not materially affect the "basic and novel properties" of the invention. Practitioners may focus on this term because if Accord's generic product includes any additional excipients (e.g., buffers, flavoring agents, or alternative stabilizers), the infringement analysis will hinge on whether those excipients materially alter the formulation's stability profile, which is the core inventive concept.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party seeking a broader scope might argue that only excipients that negatively impact the specific T4-to-T3 conversion rate should be considered "material." The claims allow for the presence of T3 impurity up to 2.5%, suggesting some tolerance for variation '538 Patent, claim 1
  • Evidence for a Narrower Interpretation: A party seeking a narrower scope could point to the patent's repeated emphasis on the benefits of a simple, "alcohol-free" ('538 Patent, col. 2:51-52) and "preservative-free" '913 Patent, claim 1 formulation. The specification's focus on achieving stability through the specific water-glycerol vehicle and multi-barrier packaging, rather than chemical stabilizers, may support an argument that the addition of almost any functional excipient would materially alter the invention's properties.

VI. Other Allegations

Indirect Infringement

• For the '538 and '913 product patents, the complaint alleges that Accord's Product is "especially adapted for a use that infringes" and that there is "no substantial non-infringing use," which are elements of contributory infringement Compl. ¶25 Compl. ¶32
• For the '382 method patent, the complaint alleges induced infringement, stating that Accord's sale and promotion of its product would "intentionally induce others to use" it in a manner that infringes the claimed methods of administration Compl. ¶39

Willful Infringement

• The complaint does not contain an explicit allegation of willful infringement. However, it alleges that Accord has had knowledge of the patents since at least the dates of its Paragraph IV notice letters Compl. ¶20 Compl. ¶21 Compl. ¶25 Compl. ¶32 Compl. ¶39 Plaintiffs also request a finding that the case is "exceptional" and an award of attorneys' fees pursuant to 35 U.S.C. § 285 Compl. ¶28 Compl. ¶35 Compl. ¶43

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of factual determination: once the specifics of Accord's proposed generic product are revealed, does its chemical composition and packaging system fall within the literal scope of the asserted claims, particularly the requirements for an "alcohol-free and preservative-free solution of 85% glycerol in water" and the specific container/sachet configuration?
• A key legal question will be one of claim scope: how will the court construe "consisting essentially of"? If Accord's product contains additional, unrecited excipients, the outcome may depend on whether those excipients are found to materially alter the claimed invention's fundamental property of enhanced stability against T4-to-T3 degradation.
• For the method-of-use patent ('382), a central question will be one of induced infringement: does the proposed label for Accord's generic product contain instructions or recommendations that would lead physicians and patients to administer the drug within the claimed time window relative to meals, and does this rise to the level of specific intent to induce infringement?